Treatment of Capd Peritonitis with Intraperitoneal Ampicillin/Sulbactam Aminoglycoside Combination
F. Ersoy,T. Sezer,M. Sarikayal,G. Süleymanlarl,G. Yakupoglul
DOI: https://doi.org/10.1177/089686089801800216
1998-03-01
Peritoneal Dialysis International
Abstract:peritonitis episodes. This change was necessary mainly because of the emergence of vancomycin resistant enterococci (1). Ampicillin-sulbactam (A/S) is a combination drug of ampicillin with a potent irreversible inhibitor of beta-Iactamases, sulbactam, in a 2:1 ratio. This combination has the advantage of having a broad spectrum, low toxicity, and enhanced activity against most beta-Iactamase producing bacteria such as E. cali, Proteus, and staphylococci including S. aureus. Compared to first-generation cephalosporins, A/S has re markably better activity against enterococci and also anaerobic organisms (2). Between February 1995 and February 1997, we evaluated the potential value of an intraperitoneal A/S-AG combination in the treatment of chronic PD-related peritonitis. The study included 75 PD related peritonitis episodes in 36 CAPD patients. Patients had a mean age of 47.3 years (34 -68 years) and had been on CAPD for an mean period of 18.3 months (1 75 months) with disconnect systems and four 2-L exchanges. Peritonitis diag nosis was established by a WBC count higher than 100/mm3, cloudy dialysate, abdominal pain, and/or fever. The day that peritonitis was diagnosed was referred to as day zero. Patients with fungal peritonitis, mycobacterial peritonitis, eosinophilic peritonitis, surgical peritonitis, diverticulosis, and catheter-related peritonitis were excluded from the study group. Successful treatment was diagnosed when cytologic, clinical, and bacteriologic normalization occurred before the fifth day of antibiotic therapy. Treatment failure was diagnosed when a remission was not obtained by the fifth day or relapse was diagnosed. A second peritonitis episode within 4 weeks after the termination of a peritonitis treatment was considered a relapse of the first peritonitis episode and counted as failure of treatment. Ampicillin-sulbactam was administered intra peritoneally (IP) as 1000 mg ampicillin + 500 mg sulbactam in each 2-L bag, while the amicacin dose was 120 mg/day and the netilmycin dose was 40 mg/ day as single nighttime IP doses following 500 mg and lOO mg loading doses, respectively. In 37 episodes amicacin, and in 38 episodes netilmycin, was chosen as the second antibiotic in order to compare their clinical effectiveness. Effluent samples (10 mL) from the first dialysis bags of day zero were collected and injected into aerobic and anaerobic BacT/Alert (Organon Teknica, Durham, NC, U.S.A.). Samples were also sent for cell count, Gram stain, and fungal cultures. A/S was administered for 21 days while AGs were discontinued at the 14th day in order to avoid Treatment of CAPD Peritonitis with Intraperitoneal